Navigation Links
ARIUS to Present at American Association for Cancer Research Annual,Meeting

- Lead Programs CD44 and Trop-2 poster Presentations Reveal New Findings -

TORONTO, April 4 - ARIUS Research Inc. (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that new information on the preclinical activity of two of its novel monoclonal antibodies will be presented at the Annual Meeting of the American Association for Cancer Research (AACR), which runs from April 14-18, 2007 in Los Angeles, California. The first poster presentation will outline the activity of ARIUS' lead anti-CD44 antibody, ARH460-16-2, against liver cancer, a significant market in Asia and a growing concern in North America.

CD44 is an important marker for cancer stem cells that often survive treatment and keep growing to spread tumors. Studies of patients with different types of cancer have shown that CD44 can be linked to poorer chances of survival. ARIUS anti-CD44 antibodies have previously been found to control tumor growth and improve survival in breast and prostate cancer models.

The second poster will describe the activity of two antibodies targeting Trop-2 in a variety of solid tumors including breast and colon cancers plus pancreatic cancer, an area without effective treatment options. Trop-2 is a new target for drugs in cancer. Recently, increasing Trop-2 has been shown to
stimulate tumor growth. Studies in colon cancer patients found it is also associated with more aggressive disease and cancer death.

"Presenting our most recent findings for two of our lead programs, CD44 and Trop-2, is an excellent opportunity to showcase the potential of our products as we look for partners," said Dr. David Young, President and CEO. "Moreover, this important preclinical work also highlights the value and capabilities of our FunctionFIRST(TM) platform to generate novel antibodies with promising anti-cancer properties."

Novel antibody ARH460-16-2 rec
'"/>




Page: 1 2 3 4

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
(Date:11/27/2009)..., BLOOMINGTON, Minn, Nov. 27 AC...dical image management software, data migration to...United States Patent and Trademark Office has appr...ion Format within a Computer Network." Acuo Techno...rtfolio of intellectual property. In general, the ...
(Date:11/25/2009)... , WESTON, Fla., Nov. 25 /PRNewswire-Firs... Sheets: ASFX) ("the Company") is pleased to annou... production management office in Shanghai, China. ...d, providing an essential gateway for the developm...d safety products for children and adults to be di...
(Date:11/25/2009)... , PHILADELPHIA, Nov. 25 /PRNewswire-First...t Dr. Michael J. McKelvey, the Company,s President...ve Vice President and CFO, are scheduled to presen...ference at 1:30 PM EST on December 1, 2009 in New ...access the presentation by visiting the Company,s ...
Breaking Medicine Technology:Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2American Scientific Resources Inc. Opens Shanghai Location 2ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Meridios Ltd Selected as a Nationwide CMS Qualified Registry to Report Healthcare Quality Measures 48726 1Meridios Ltd Selected as a Nationwide CMS Qualified Registry to Report Healthcare Quality Measures 48726 2Actuaries Urge Need for Risk Management and Continuity Planning With H1N1 Pandemic 48724 1Actuaries Urge Need for Risk Management and Continuity Planning With H1N1 Pandemic 48724 2Actuaries Urge Need for Risk Management and Continuity Planning With H1N1 Pandemic 48724 3Aviation Law Expert Offers Guidance on How Families of Air France Flight 447 May Seek Compensation from Airline 48721 1Aviation Law Expert Offers Guidance on How Families of Air France Flight 447 May Seek Compensation from Airline 48721 2
...cus Attention on a New Ab...ation Frontiers, Inc.,today announced that two stu...trial fibrillation catheter ablation system were p... a premier meeting for physicians that,treat cardi...versity Clinic at Regensburg, Germany,presented re...
...ences, Inc. (Nasdaq: PBIO ) ("PBI" and "the Compa...ase II Small Business Innovation Research,(SBIR) G...s of Health,(NIH). The Grant will help fund contin...and commercialization of novel, automated, and rep... important protein biomarkers,subcellular molecula...
Other Medicine Technology:Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times 2Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times 3Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery 2Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery 3Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery 4
(Date:11/27/2009)...7 GSI Group Inc. (Pink S...ion technology products and semiconductor systems,...pany,s shareholders has been scheduled for Friday,...ting will be announced in due course. As previous...otice from Stephen Bershad, a holder of greater th...
(Date:11/27/2009)...PRNewswire-FirstCall/ -- The Gymboree Corporation .../COO, will present at the NASDAQ OMX 23rd Investor... in London, England, on Wednesday, December 2, 200...oadcast of The Gymboree Corporation,s presentation...com, click on "Our Company" at the bottom of the p...
(Date:11/27/2009)...Holdings has announced that it has become a nation... largest nonprofit organizations dedicated to arth... Delray Beach, FL (Vocus) Nove...CHO), a company specializing in the marketing and ...s, has announced today that is has become a nation...
(Date:11/27/2009)...alth™ announced today that Spectrum Health (... Enterprise orthopedic templating solution and its... (PRWEB) November 27, 2009 -- Voyant ... (Grand Rapids, Michigan) has licensed its TraumaC...ts TraumaCad Extend workflow solution, to allow it...
(Date:11/26/2009)...wswire/ -- With cold and flu season upon us, it,s ...to control the spread of infections and avoid illn...ep ourselves healthy, but to avoid transmitting il... CIC (certified in infection-control), nursing dir...h at Hospital for Special Surgery (HSS) in Manhatt...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4
...developed a gel that it says can treat hypogonadis...dism is a condition that causes reduced libido, er...y, and irritability. Like women who grow l... male libido and sexual function, as well as muscl...
...nown for its religious fervour, is emerging as a h...s as Astrology Doctors . Many claim that t... kidney-related problems and others, with their ge...tones are prescribed for patients after studying t...
...as found that diabetes is associated with decrease... developing heart disease . The study, pub...e JAMA/Archives journals, shows that men and women...ut diabetes. Globalization of the Western ...
...search team has identified a gene that, when mutat...rited blindness in babies . Scientists at ...experts from other centres around the world, disco...rs congenital amaurosis (LCA), comes at a time of ...
...iyo Mori said Monday she had confidence in herself...onal Japanese women who are often seen as timid. ... to Japan," Mori, 20, told her first news conferen...Fuji last month became the second Japanese to be c...
...cessfully eased the symptoms of Parkinson's diseas...splants . During the course of study, publ...f Sciences, the scientists isolated stem cells fro...monkeys with a severe form of chemically induced P...
Other Medicine News:Health News:Is Gemstone-therapy an Alternative to Treat Illness? 2Health News:Diabetes Reduces Life Expectancy, Increases Heart Disease Risk 2Health News:New Gene Discovery Raises Hope for Childhood Blindness Cure 2Health News:New Gene Discovery Raises Hope for Childhood Blindness Cure 3
SureStep Benzodiazepines (BZO 200)
SureStep Propoxyphene (PPX)
SureStep Tricyclic antidepressants (TCA)
THC/COC/MOP/AMPII/MAMPII/BZO200
Medicine Products: